Therorna Closes Series A Financing of RMB 280 Million, with CEC Capital as Exclusive Financial Advisor

Therorna Inc. is dedicated to the development of novel vaccines and therapies in multiple cutting-edge treatment areas, focusing on international frontier circular RNA (circRNA) technology. This funding round was led by MSA Capital and a renowned industrial investment institution, with participation from Sherpa Healthcare Partners and 3H Health, as well existing shareholders Quan Capital and Cenova Capital.

CEC Capital Group acted as the exclusive financial advisor for Therorna in this transaction.

Following this financing, the company will expedite the development of their technological platform, pipeline products, clinical trials, registration applications, and international collaborations.